newsfilter
← Latest News
PR Newswire·

Seqirus Co-Authors First Study to Assess Simultaneous Administration of Seasonal Influenza Vaccine and COVID-19 Vaccine Candidate

SUMMIT, N.J., June 14, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a division of CSL Limited (ASX: CSL), today announced that the company co-authored the first study to demonstrate the safety, immunogenicity and efficacy pro